Islets of Hope diabetes news headlines

                            Diabetes Drug R & D

Headline News and Stories Relating to Current and Future Diabetes Drug Research and Development

If you copy our list of links for your own site, we'd really appreciate it if you would add a link to our site as well.  Your support and mention of www.IsletsofHope.com will help others with diabetes.  We now donate 100% of the profits from our website to nonprofit diabetes organizations that purchase insulin, diabetes medications, and supplies for others in need.

|  Business  | Diabetes Events | Drug Research & Development  |  Education  | General Diabetes Studies  |  Human Interest  |
|  Legislation - Diabetes, Ethics, Research  | Stem Cell Research  | Your Diabetes Health | Technology (Diabetes)  |
|  FDA, UK & European Drug & Medical Updates Approvals/Rejections/Warnings
|  RECALLS & WARNINGS for Diabetes Medications, Products & Devices  |

November 2006

See "Current Headlines"

October 2006

• Drug Could Provide New Treatment Approach For Overweight People With Diabetes - Medical News Today - October 31, 2006 - The drug rimonabant, can reduce bodyweight and improve control of blood glucose levels and other cardiovascular risk factors in people with type 2 diabetes, according to an Article in this week's issue of The Lancet. The findings suggest that this drug could be used as a new approach for treatment of diabetes where other drugs have failed.
• Generex Biotechnology Clinical Data to Be Presented at 6th Annual Diabetes Technology Meeting - Market Wire via Yahoo! Finance - October 31, 2006 - Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will make two poster presentations of clinical data at the 6th Annual Diabetes Technology Meeting in Atlanta, Georgia, November 2 - 4, 2006. The data relates to Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product ...
• Milk Thistle May Help Treat Diabetes - WebMD - October 31, 2006, - An extract made from milk thistle seeds may help control blood sugar in people with type 2 diabetes, Iranian researchers say.
• Herbal medicine could hold cure for type II diabetes - New Kerala - October 31, 2006 - Washington, Oct 31: A herbal medicine extracted from seeds of the milk thistle, Silybum marianum (silymarin) may help sugar-control in people with type II diabetes, according to a research.
• Local study tests new diabetes treatment - WTHR Indianapolis - October 30, 2006 - Indianapolis - A Hoosier doctor is leading the global clincial trial of a novel approach to treating diabetes. They are now enrolling patients and they are flying in for treatment.
• The efficacy of Silybum marianum (L.) Gaertn. (Silymarin) in the treatment of type II diabetes - News-Medical-Net - October 30, 2006
• Sleep Medicine: Sleep Apnea And Diabetes - Medical News Today - October 30, 2006 - Sleep Apnea and Diabetes May Be RelatedAccording to new research, obstructive sleep apnea syndrome (OSAS) and diabetes mellitus (DM) may be associated. Using the electronic charts of patients referred for sleep studies over one year, researchers from Quillen College of Medicine in Tennessee identified 127 patients with DM.
• Herbal Medicine Silymarin May Help Sugar-control In People With Type II Diabetes - Science Daily - October 30, 2006
• Diabetes treatment: Medications for type 2 diabetes - Mayo Clinic - October 28, 2006 - Here's a comparison of various types of oral and injectable diabetes medications.
• Obesity drug may help Type 2 diabetes - CBC - October 27, 2006
• Obesity pill may treat diabetes - Reuters via Yahoo! News - October 27, 2006
• Obesity pill could treat diabetes - AAP via Yahoo!7 News - October 27, 2006
• Obesity pill seen as new way to treat diabetes - Reuters via Yahoo! Asia News - October 26, 2006
• Acomplia May Be Effective for Diabetes - WebMD - October 26, 2006 - Acomplia, a highly anticipated weight loss drug, may also be an effective treatment for type 2 diabetes.
• Alantos, Servier tie up for diabetes drug - PharmaBiz - October 26, 2006 - Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II has formed a collaboration with Servier, the leading French independent pharmaceutical company, surrounding its lead compound ALS 2-0426...
• New anti-diabetes drug to cut costs - Interfax - October 24, 2006 - East China University of Science and Technology and Shandong Lunan Pharmaceutical Ltd. have jointly developed a diabetes drug using new technology which will slash production costs.
• Widely Prescribed Diabetes Drug Falls Short Of Promise, Says New Review - Science Daily - October 21, 2006 - A new systematic review calls into question the health benefits versus risks of an oral medicine widely prescribed for diabetes throughout the United States, Canada, Europe and Asia. The drug -- called pioglitazone -- is marketed in the United States by Takeda Pharmaceuticals North America, Inc., and Eli Lilly and Co. under the trade name Actos.
• FDA Approves New Oral Drug to Treat Type 2 Diabetes - RedNova - October 21, 2006 - By Los Angeles Times WASHINGTON -- Federal regulators on Tuesday approved a new class of oral drugs for Type 2 diabetes that are as effective as most existing treatments and avoid common side effects, such as dangerously low blood sugar.
• Glenmark Pharma And Merck KGaA Announce Collaboration Agreement On DPPIV Inhibitor For Type 2 Diabetes - Nasdaq - October 17, 2006 - (RTTNews) - Glenmark Pharma informed that Merck KGaA and Glenmark Pharmaceuticals S.A.Switzerland, a wholly owned subsidiary of the company, entered into an agreement for Glenmark's DPPIV inhibitor GRC 8200, a treatment for type 2 diabetes in Phase II of clinical development.
• Diabetes Drugs Could Stop Deadly Sepsis - MedicineNet.com - October 13, 2006
• Firms eye current drugs to stem diabetes - UPI - October 13, 2006 - Physicians and drug makers in the United States are examining whether drugs used to treat diabetes can prevent the disease in others who may be at risk.
• Thousands of Students Join Diabetes Study - RedNova - October 13, 2006
• Novartis launches head on study with Galvus and oral diabetes pills - PharmaBiz - October 13, 2006, - Novartis announced the start of Galiant, a significant clinical trial set to involve more than 7,500 people in the United States comparing the investigational oral type 2 diabetes medication Galvus (vildagliptin) with commonly prescribed anti-diabetic oral medicines called thiazolidinediones (TZDs).
• Novartis launches diabetes comparison trial - Pharmaceutical Business Review - October 13, 2006
• Novartis launches head on study with Galvus and oral diabetes pills - PharmaBiz - October 13, 2006, 03:46 GMT.  Novartis announced the start of Galiant, a significant clinical trial set to involve more than 7,500 people in the United States comparing the investigational oral type 2 diabetes medication Galvus (vildagliptin) with commonly prescribed anti-diabetic oral medicines called thiazolidinediones (TZDs).
• Novartis launches diabetes comparison trial - Pharmaceutical Business Review - October 13, 2006
• Diabetes Drugs Could Stop Deadly Sepsis - HealthDay via Yahoo! News - October 12, 2006, 20:03 GMT.  A new class of diabetes drugs appears to hold promise against sepsis, Texas researchers report.
• ASCOT's trial proves Amlodipine-based regimen reduced diabetes risk by 34 % in BP patients - PharmaBiz - October 12, 2006, 10:46 GMT.  The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the world's largest study of hypertensive patients has proved that Amlodipine-based regimen reduces risk of new-onset diabetes by 34 per cent in hypertensive patients.
• MacroGenics Receives Orphan Drug Designation From FDA for Monoclonal Antibody to Treat Type 1 Diabetes - PR Newswire via Yahoo! Finance - October 10, 2006, 11:00 GMT.  MacroGenics, Inc. announced today that its lead product candidate, MGA031, a humanized, Fc-engineered anti-CD3 monoclonal antibody, has received orphan drug designation from the Food and Drug Administration for treatment of recent-onset type 1 diabetes mellitus .
• MacroGenics Receives Orphan Drug Designation From FDA For Monoclonal Antibody To Treat Type 1 Diabetes - Medical News Today - October 11, 2006
• MacroGenics diabetes drug given orphan status - Pharmaceutical Business Review - October 11, 2006
• Scientists predict diabetes, HIV vaccine development - Australian Broadcasting Corporation - October 9, 2006, 02:24 GMT.  Scientists say Australians could be vaccinated against diseases like diabetes within a few decades. The vaccines are one of several medical advances predicted in a new paper produced by 10 of the country's top scientists.
• Scientists predict diabetes, HIV vaccine development - ABC via Yahoo!7 News - October 9, 2006
• Ask Dr. H | New drug praised for diabetes - Philly.com - October 9, 2006, 07:15 GMT.  Question: I've been on a new diabetes medication called Byetta for the last three months, and it is fantastic! Not only are my blood sugars better, but I've lost 15 pounds. I just don't get hungry like I used to. How does it work? Can it be used just for weight loss?
• NZ scientists' diabetes breakthrough - TVNZ - October 3, 2006, 21:46 GMT.  Chemists have the tools to design a new drug to combat diabetes thanks to a breakthrough by scientists at Auckland University. Researchers at the Wilkins Centre for Molecular Biodiscovery have mapped the structure of an enzyme which breaks down important sugars.

Back to Top

September 2006

• Merck's Diabetes Drug Effective With Metformin in Study - Merck & Co has announced that data from its phase III study of investigational diabetes drug Januvia used in conjunction with metformin significantly lowered glucose levels in patients.  09/14/2006
• Novartis says tests successful for diabetes drug Galvus, MS drug FTY720 - The Swiss pharmaceutical company said Galvus showed equivalent efficacy to the diabetes medicine rosiglitazone, an insulin sensitizer known as a thiazolidinedione, in a head-to-head monotherapy study that led to an overall 1.8 pct reduction in blood sugar levels.  09/14/2006
• Actos May Cut Heart Attack Risk in Diabetes Patients - Takeda's diabetic drug Actos may have benefits beyond glycemic control and reduce the risk of heart attack and strokes in patients with type two diabetes, according to a study.  09/14/2006
• Diabetes could cripple health budgets, says expert - Europe's growing diabetes epidemic could cripple healthcare budgets in coming decades, particularly in eastern countries, an expert warned on Thursday.  09/14/2006
• Merck heats up diabetes drug competition - Merck announced Thursday that its experimental diabetes drug Januvia significantly lowers blood-sugar level when taken with another drug.  09/14/2006
• Merck says diabetes drug trial shows efficacy - Merck said its diabetes drug candidate Januvia, when combined with another treatment, lowered blood sugar to reasonable levels.  09/14/2006
• Lilly diabetes drug curbs weight gain - The study found that 18 percent of Type 2 diabetes patients given exenatide reached target blood sugar levels recommended by the International Diabetes Federation, compared with 9 percent of patients taking Novo Nordisk\'s NovoMix 30 insulin treatment.  09/14/2006
• Lilly Diabetes Drug Curbs Weight Gain - Drug makers Eli Lilly & Co. and Amylin Pharmaceuticals Inc. said Thursday a clinical study showed that their diabetes treatment exenatide was as effective as insulin in lowering blood sugar levels but without the weight gain.  09/14/2006
• Pfizer says Exubera works in diabetes patients with cold or flu - Pfizer's Exubera, the inhaled form of insulin works even if the diabetic patient has a cold or flu, researchers said at the 42nd annual meeting of the European Association for the Study of Diabetes.  09/14/2006
• New drug could cure diabetes - Type 1 diabetes develops when your pancreas stops making insulin, what the body needs to break down sugar. Nobody knows why this happens, and there's no cure for it.  09/14/2006
• Significant Glucose-Lowering Efficacy Of Sitagliptin, Investigational Drug For Type 2 Diabetes, When Taken With - New data presented for the first time today at the 42nd annual meeting of the European Association for the Study of Diabetes (EASD) in Copenhagen demonstrated in patients off therapy at randomization a significant mean placebo-subtracted reduction in HbA1c of 2.   09/14/2006
• Pfizer says Exubera effective in diabetes patients with respiratory infections - These analyses were presented today at the 42nd European Association for the Study of Diabetes, the company said.  09/14/2006
• Exubera Effective in Diabetes Patients with Respiratory Infections or are Exposed to Passive Cigarette Smoke, New - Twice as Many People With Uncontrolled Type 2 Diabetes Would Accept Insulin if Offered Exubera, Even in Countries Where Pens are Commonly Used, Additional Study Shows - Patients With ...  09/14/2006
• (AFX UK Focus) 2006-09-14 07:05 GMT: Novartis says tests successful for diabetes drug Galvus, MS drug FTY720 - Novartis said diabetes drug Galvus showed powerful blood sugar reductions in Phase III studies without the side effects associated with many anti-diabetic drugs.  09/14/2006
• Novartis Diabetes Drug Has Less Side Effects Claims Study - Novartis has claimed that phase III studies of its investigational type 2 diabetes drug Galvus show the drug to be as effective as GlaxoSmithKline's established Avandia but without the weight-gain side effects commonly associated with the treatment.  09/14/2006
• Final Results of PC-DAC(TM):Exendin-4 Phase I/II Trial for Type 2 Diabetes Confirm Excellent Tolerability, Positive - ConjuChem Biotechnologies Inc. today announced that final data from its Phase I/II single escalating dose clinical study for the treatment of Type 2 diabetes using the Company's proprietary PC-DAC:Exendin-4 compound confirmed the excellent tolerability profile, positive efficacy on glucose reduction and extended duration of activity reported as preliminary data on April 26th, 2006.  09/12/2006
• Symlin drug improves glucose control in diabetes patients: Amylin - Amylin Pharmaceuticals, Inc. announced positive results from a 16-week study evaluating the safety and efficacy of adding Symlin (pramlintide acetate) to an established regimen of basal insulin glargine (with or without oral antidiabetic agents) in patients with type 2 diabetes who have not progressed to mealtime insulin therapy.  09/09/2006
• Drug unlikely to slow type 2 diabetes progression - Treating "postprandial hyperglycemia" -- the spike in blood sugar that occur after meals -- with the drug Precose (also known as acarbose) does not delay the progression of early type 2 diabetes, according to a study.  09/08/2006
• SYMLIN Improved Diabetes Control In Patients With Type 2 Diabetes On Established Regimens Of Basal Insulin - Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN) today announced positive results from a 16-week studyevaluating the safety and efficacy of adding SYMLIN(R) (pramlintideacetate) to an established regimen of basal insulin glargine (with orwithout oral antidiabetic agents) in patients with type 2 diabetes who havenot progressed to mealtime insulin therapy.  09/08/2006
• Juvenile Diabetes Controlled With Nutritional Supplements - Juvenile diabetes, nutritional supplements, Type 2 symptoms, natural cures for diabetes and weight loss are some of the health related articles just released by ChristiaNet, Inc. 09/08/2006
• Xenical shown to reduce weight in diabetes patients – 09/08/2006
• Diabetes risk down three times with newer hypertension drugs - According to researchers patients given a mix of modern blood pressure drugs are one-third less likely to develop diabetes than those on older pills.  09/07/2006
• Taking preventive medications curbs diabetes risk - Individuals at risk for developing type 2 diabetes who are prescribed the drug metformin should stick with it, doctors say. In a large study, individuals who adhered to a metformin-based diabetes preventive strategy had a reduced risk of developing diabetes, they report.  09/07/2006
• Taking preventive medications curbs diabetes risk - Individuals at risk for developing type 2 diabetes who are prescribed the drug metformin should stick with it, doctors say.  09/07/2006
• Betablockers linked to diabetes - The use of betablockers to treat high blood pressure may be causing up to 8,000 additional cases of diabetes in Britain each year, researchers at Imperial College London claim.  09/07/2006
• SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes on Established Regimens of Basal Insulin - Amylin Pharmaceuticals, Inc. today announced positive results from a 16-week study evaluating the safety and efficacy of adding SYMLIN(R) to an established regimen of basal insulin glargine in patients with type 2 diabetes who have not progressed to mealtime insulin therapy.  09/07/2006
• (AFX UK Focus) 2006-09-07 06:50 GMT: Roche says Xenical improves blood sugar levels in type II diabetes patients - 09/07/2006
• Xenical(R) Shown to Improve Control of Blood Glucose Levels in People With Type 2 Diabetes Beyond Impact of Weight Loss - 09/07/2006
• Beta-blockers 'increase diabetes risk by 50 per cent' - Patients taking beta-blockers for their blood pressure have a 50 per cent higher risk of developing diabetes compared to being on newer drugs. A new study has revealed the risk of using the older drugs which are no longer recommended for treating high blood pressure … 09/06/2006
• Beta-blockers 'increase diabetes risk by 50 per cent' - Patients taking beta-blockers for their blood pressure have a 50 per cent higher risk of developing diabetes compared to being on newer drugs, researchers have revealed.  09/06/2006
• Study says Pfizer's hypertensive drug decreases risk of diabetes - New findings from Europe's biggest trial of hypertensive patients shows that Pfizer Inc.'s hypertension drug Norvasc is quite promising in preventing the occurrence of diabetes in patients with high blood pressure.  09/06/2006
• New Once-Daily Oral Diabetes Treatment Glumetza(TM) Now Available - Adult patients living with type 2 diabetes now have a new treatment option available that may help them get the most out of their care.  09/06/2006
• Amlodipine Based Regimen to Lower Blood Pressure, Reduces the Risk of New-Onset Diabetes in Hypertensive Patients by - A hypertension regimen based on the calcium channel blocker amlodipine has been shown to reduce the risk of new-onset diabetes by 34 percent in people with high blood pressure, compared with a widely used beta-blocker-based antihypertensive regimen, according to findings from the largest study of hypertensive patients ever conducted in Europe .  09/06/2006
• New hypertension pills cut diabetes risk by third - Patients given a mix of modern blood pressure drugs are one-third less likely to develop diabetes than those on older pills, researchers said on Wednesday.  09/06/2006
• Amlodipine based regimen reduces risk of new-onset diabetes - 09/06/2006
• Takeda's Actos Reduces Stroke Risk in Diabetes Study - A trial of Takeda's oral antidiabetic Actos has shown the drug to be capable of significantly reducing the incidence of stroke by almost 50% in high-risk patients with type 2 diabetes.  09/04/2006
• Takeda diabetes drug slashes risk of second stroke - Patients with type 2 diabetes who have already suffered a first stroke have 47 percent less risk of having a second one if they take Takeda Pharmaceutical Co. Ltd's drug Actos, researchers said on Sunday.  09/03/2006
• Takeda diabetes drug slashes risk of second stroke - 09/03/2006
• Ajinomoto, Sankyo sign pact for diabetes drug - 09/02/2006
• Ajinomoto, Sankyo In Joint Development, Manufacture And Marketing Of AJD101, New Diabetes Drug - Ajinomoto and Sankyo announced an agreement on August 31 which will grant Sankyo exclusive global rights to develop, manufacture and market the new diabetes drug AJD101 and related compounds currently being developed by Ajinomoto.

Back to Top

August 2006

• The diabetes drugs we didn't know we had?   -- Two drugs used to treat liver disorders could be turned against obesity-related diabetes.  08/30/2006
• Understand the Key Factors That Will Contribute To the Success of the Next Generation of Anti-Diabetes Drugs  08/30/2006
• Diamyd's Type 1 diabetes drug shows efficacy - Diamyd Medical has announces that its lead drug candidate, Diamyd, has demonstrated overall statistically significant efficacy in preserving insulin production in a phase II clinical trial in 70 children and adolescents with type 1 diabetes.  08/29/2006
• Oral Medications Can Replace Insulin for Many With Rare Neonatal Diabetes - Researchers have very good news for most people who were diagnosed with diabetes in infancy: There's a good chance you can switch from injected insulin to an oral medication.  08/02/2006
• Diabetes drug side effect is weight loss - Side effects are usually the last thing drug companies want to hear about, but a new diabetes medication (BYETTA) seems to come with a welcome added benefit: weight loss.  08/01/2006

Back to Top

July 2006

• FDA Approves Takeda's Diabetes Combo - Takeda's US subsidiary has received FDA approval for its new drug application for Duetact in type 2 diabetes. Duetact combines Actos (pioglitazone HCl) and glimepiride, two widely used diabetes medications with complementary actions, in a single tablet.  07/31/2006
• FDA Approves duetact(TM) (pioglitazone HCl and glimepiride) for the Treatment of Type 2 Diabetes - Takeda Pharmaceuticals North America, Inc. announced that the U.S. Food and Drug Administration has approved the New Drug Application for duetact , pronounced "Duet Act," for the treatment of type 2 diabetes.  07/31/2006
• NicOx moves diabetes drug into phase II - Following promising results in previous trials, NicOx SA has opted to move NCX 4016 forward in clinical development as a novel insulin sensitizing agent for the treatment of type 2 diabetes.  07/28/2006
• NicOx Moves Diabetes Drug into Phase II – 07/27/2006
• NicOx To Move NCX 4016 Forward In Phase 2 For Diabetes – 07/27/2006
• Novartis' Neoral Lowers Diabetes Incidence After Kidney Transplant - A large-scale head-to-head study has shown that Novartis' Neoral and the widely used tacrolimus have equivalent efficacy in preventing organ rejection in kidney transplant patients, but those treated with Neoral had a significantly lower incidence of new-onset diabetes.  07/25/2006
• Cancer Drug Could Be Cure For Diabetes - A drug used to treat cancer patients might be the key to curing Type I Diabetes, and the good news is that study is being conducted in our own backyard.  07/28/2006
• Drug combo works well for diabetes and high lipids - For people with diabetes who also have abnormal levels of blood fats, or lipids, the combination of two types of cholesterol-lowering drugs seems to work better than either one alone, researchers report.  07/27/2006
• Diabetes treatments may help Alzheimers - meeting - Diabetes and pre-diabetic conditions appear to worsen the risk of Alzheimer's disease but drugs that help regulate blood sugar may help patients with dementia as well, researchers report.  07/17/2006
• Diabetes Drug Shows Promise In Treating Alzheimer's - A drug for type 2 diabetes shows promise in safety tests for treating Alzheimer's Disease as well without serious side effects.  07/17/2006
• New diabetes drug may have welcome side effect: weight loss - The Washington University Diabetes Center at Barnes-Jewish Hospital focuses on providing patients with the latest technology, treatments and clinical research. Some patients at the center are receiving a new diabetes drug that may give a welcome side effect - weight loss.  07/14/2006
• GSK's Avandamet gets US FDA approval for initial therapy in type 2 diabetes  - GlaxoSmithKline announced that US FDA approved Avandamet (rosiglitazone maleate and metformin HCl) for use as initial treatment of type 2 diabetes as an adjunct to diet and exercise.  07/12/2006
• Caraco Receives Diabetes Drug Approval - Generic drug maker Caraco Pharmaceutical Laboratories Ltd. said Wednesday it received U.S. Food and Drug Administration approval of a generic version of Pfizer Inc.'s diabetes drug Glucotrol.  07/12/2006
• GlaxoSmithKline Diabetes Drug Receives FDA Approval As Initial Therapy - Avandamet, a diabetes drug from GlaxoSmithKline, can now be used as an initial treatment for type 2 diabetes.  07/12/2006
• CDRI developing unique drug for diabetes related hyperlipidemia - The Central Drug Research Institute (CDRI), Lucknow, in association with the Bangalore based Connexios Life Sciences is developing a breakthrough drug for controlling blood sugar as well as lipid level in the area of diabetes and associated hyperlipidemia.  07/11/2006

Back to Top

June 2006

• New Study Shows Cinnamon Extract Lowers Blood Sugar Levels In People With Type 2 Diabetes - A water-soluble, cinnamonextract has been shown to reduce fasting blood sugar levels in patientswith type 2 diabetes, according to a new study from the University ofHannover in Hannover, Germany published in a recent issue of the EuropeanJournal of Clinical Investigation.  06/30/2006
• Health Alert: Diabetes chemo - A cancer treatment is now being tested as a way to control diabetes. Testing her blood is something Kimberly Parker is still getting used to.  06/28/2006
• Dia-B Advances Research On Anti-diabetes Compound - Melbourne biotech group Dia-B expects to begin clinical trials of its ISF402 anti-diabetes compound in the last quarter of 2006 after initial trials on animals proved that the compound is effective in lowering blood glucose levels.  06/26/2006
• Nastech, Amylin Enter Diabetes Pact - (AP) BOTHELL, Wash. Shares of Nastech Pharmaceutical Co. gained Monday after the drug delivery technology maker announced an agreement with drug maker Amylin Pharmaceuticals Inc. to help develop a diabetes treatment in a nasal spray.  06/26/2006
• Nastech, Amylin Enter Diabetes Pact - Shares of Nastech Pharmaceutical Co. gained Monday after the drug delivery technology maker announced an agreement with drug maker Amylin Pharmaceuticals Inc. to help develop a diabetes treatment in a nasal spray.  06/26/2006
• Drug shows promise in blocking diabetes - The nation's 20.8 million diabetics didn't have a medication available to them to prevent the onset of the debilitating disease. But if a promising new drug being studied in San Antonio eventually gets FDA approval, 41 million pre-diabetics may be able to stave off the disease and the potentially deadly risk factors that come with it.  06/26/2006
• Diabetes drug trial to start in 6 months - A Melbourne company is expected to begin human trials of a new oral drug to treat type 2 diabetes within six months.  Biotech group Dia-B Tech Ltd today announced it expected to begin clinical trials of its ISF402 anti-diabetes drug later this year.  06/23/2006
• New drugs generating optimism on diabetes - Even as diabetes rates reach epidemic levels worldwide, four new drugs are generating optimism among doctors.  06/22/2006
• Four Diabetes Drugs Raise Hope -  Doctors say the new drugs are important additions to the treatment arsenal because they work differently from existing diabetes medicines and have relatively mild side effects.  06/22/2006
• 4 Diabetes Drugs Are Seen Raising Hope and Profit -  Even as diabetes rates reach epidemic levels worldwide, four new drugs are generating optimism among doctors as well as Wall Street analysts.  06/22/2006
• The Molecular Mechanism Of A Diabetes Vaccine Revealed -  A team of researchers led by Prof. Irun Cohen of the Weizmann Institute of Science Immunology Department has revealed the molecular mechanism of a vaccine for Type 1 diabetes. The new findings should help amplify the effectiveness of the vaccine, which is currently in advanced stages of clinical trials.  06/22/2006
• Molecular Mechanism Of A Diabetes Vaccine Revealed - A team of researchers led by Prof. Irun Cohen of the Weizmann Institute of Science Immunology Department has revealed the molecular mechanism of a vaccine for Type 1 diabetes. The new findings should help amplify the effectiveness of the vaccine, which is currently in advanced stages of clinical trials.  06/20/2006
• Diabetes pills lower blood sugar, weight too - Washington - Two experimental pills seem to help older diabetes drugs lower patients' blood sugar, with the added...  06/19/2006
• New diabetes and metabolic disorders drugs waiting in pipeline for Plexxikon - Every quarter, Plexxikon Inc. CEO Peter Hirth and his top executives sit down to do a little triage. They determine which projects will continue and which ones will be shelved.  06/19/2006
• Positive Phase III Data for Novartis' Diabetes Drug - Novartis' investigational drug candidate Galvus, a new once-daily oral treatment option for type 2 diabetes, has demonstrated impressive efficacy, especially in patients with poor glycemic control, as well as weight loss benefits in obese patients.  06/16/2006
• Aliskiren superior to ramipril to control diabetes and hypertension: Novartis - Newly-released clinical data show that Rasilez (aliskiren), the first orally effective direct renin inhibitor, provided superior reductions in systolic blood pressure over the ACE inhibitor ramipril in people with diabetes and hypertension.  06/16/2006
• Positive phase III data for Novartis' diabetes drug - Novartis investigational drug candidate Galvus, a new once-daily oral treatment option for type 2 diabetes, has demonstrated impressive efficacy, especially in patients with poor glycemic control, as well as weight loss benefits in obese patients.  06/16/2006
• Auxilium Pharmaceuticals Announces Top-Line Results From Phase IV Trial Of Testim(R) In Patients With Type II Diabetes - Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty pharmaceutical company,today reported top-line results from its Phase IV randomized trial ofTestim(R) 1%, its topical testosterone gel, treatment in patients with Type II diabetes.   06/16/2006
• Mixed Results for Auxilium Drug in Diabetes Study - Auxilium Pharmaceuticals Inc., a specialty pharmaceutical company in Malvern, said today a study of its topical testosterone gel helped men with Type II diabetes lose fat and gain muscle in a clinical trial.  06/16/2006
• Isis Diabetes Drug Improves Glucose Control in Phase II Trial - Isis Pharmaceuticals has obtained positive results from a phase II trial evaluating ISIS 113715, a novel insulin sensitizer, as a single-agent in patients with type 2 diabetes.  06/15/2006
• New Type 2 Diabetes Drugs at FDA Stage -  Merck & Co. and Novartis AG are seeking U.S. government approval of new Type 2 diabetes drugs they claim have milder side effects than current treatments.  06/15/2006
• Pfizer, Bayer team up to develop diabetes and obesity compounds - Pfizer Inc. received exclusive worldwide rights to a class of Bayer Pharmaceuticals Corp. compounds that could lead to treatments for diabetes and obesity, the companies said.  06/14/2006
• New Drugs Show Promise in Controlling Diabetes - A new class of experimental drugs that aids hormones in the gut can significantly lower high blood sugar in people with type 2 diabetes without causing weight gain or other side effects, researchers said Tuesday.  06/14/2006
• Novartis, Merck Diabetes Drugs Very Similar - New diabetes drugs from Novartis (NVS) and Merck (MRK), presented at a major medical conference, appear to be broadly similar in terms of efficacy and safety, analysts say.  06/14/2006
• Novartis Unveils Further Impressive Efficacy Data For Galvus(R), An Investigational Oral Diabetes Compound, Showing - Galvus(R)(vildagliptin), seeking to become a new once-daily oral treatment optionfor type 2 diabetes, has demonstrated impressive efficacy, especially inpatients with poor glycemic control, as well as weight loss benefits inobese patients.  06/14/2006
• Next diabetes drugs seem to keep the weight off - A new class of diabetes drugs can control blood sugar without causing weight gain and potentially could slow the progression of this increasingly prevalent disease, new research shows.  06/14/2006
• 2 Diabetes Drugs May Lower Blood Sugar - Two experimental pills seem to help older diabetes drugs lower patients' blood sugar, with the added bonus of a little weight loss.  06/14/2006
• New drugs show hope in controlling diabetes - A new class of experimental drugs that aids hormones in the gut can significantly lower high blood sugar in people with type 2 diabetes without causing weight gain or other side effects, researchers said Tuesday. Experts welcome the new therapies.  06/14/2006
• Merck says diabetes drug on par with standard care - A diabetes drug awaiting U.S. approval helped lower blood sugar levels comparable to a conventional treatment and also helped patients lose weight, the drug's developer, Merck & Co. , said on Tuesday.  06/13/2006
• Novo Nordisk diabetes drug highly effective: study - An experimental diabetes drug by Novo Nordisk dramatically improved blood sugar levels and lowered weight in type 2 diabetes patients in a mid-stage clinical trial, researchers said on Tuesday.  06/13/2006
• New Diabetes Drug May Lower Blood Sugar and Weight - A new diabetes drug lowers patients' blood sugar and also helps shed some pounds.  06/13/2006
• Merck Issues New Data on Diabetes Drug - Drug maker Merck & Co. said Tuesday that clinical data showed its Januvia diabetes treatment was not inferior to a standard treatment and significantly cut down on weight gain.  06/13/2006
• New diabetes drugs may aid weight loss - More than 230 million people worldwide have diabetes, up from just 30 million in 1985, according to the International Diabetes Federation. Diabetes is expected to affect 350 million people by 2025.   06/13/2006
• New diabetes drugs give double punch - Two experimental pills seem to help older diabetes drugs lower patients' blood sugar, with the added bonus of a little weight loss.  06/13/2006
• Novartis diabetes drug effective in combo study - A Novartis AG diabetes drug currently awaiting U.S. approval significantly reduced blood sugar levels in patients with type 2 diabetes when given in combination with an older medicine called pioglitazone, researchers said on Tuesday.  06/13/2006
• Isis Posts Diabetes Drug Study Data - Drug maker Isis Pharmaceuticals Inc. said Tuesday that its experimental diabetes treatment significantly improved measures of blood sugar control in newly diagnosed patients in a mid-stage clinical study, but blood sugar over a three-month average was not significantly improved.  06/13/2006
• Acomplia Cuts Diabetes Patients' Risks - Acomplia, an experimental weight loss drug, helps obese people with type 2 diabetes lose weight, reduce waist size, and even control blood sugar and blood fats.  06/12/2006
• Medical News: Coffee, Diabetes, Food Allergies - In Monday's medical news, NewsCenter 5's Heather Unruh reported on a healthy perk if you have coffee cravings, a pill that could tackle a serious side effect of diabetes, and how to make sense of your baby's food allergies.  06/12/2006
• OSI Pharmaceuticals Reports Positive Diabetes Data - The drugmaker announced positive Phase II trial data for its lead diabetes drug candidate.  06/12/2006
• Oramed Pharmaceuticals Combats Diabetes with Oral Insulin - Oramed Pharmaceuticals' (OTCBB: ORMP) (the 'Company') is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally ingestible soft gel insulin   06/12/2006
• Antidepressants may increase diabetes risk - Study findings show that there is a link between the use of antidepressant drugs and diabetes, investigators here at the 66th Scientific Sessions of the American Diabetes Association announced. This is the first report of such an association, they say.  06/12/2006
•  Dia-B Believes Bark Could Help Diabetes Sufferers  - Melbourne based biotechnology group Dia-B Tech Limited believes that it has found a natural alternative to anti-diabetes drug insulin in the bark of a species of vine found in rainforests of the Pacific Islands. The chemical component produced from the vine occurs in traditional medicines but it has not been used for anti-diabetic or hypoglycaemic purposes.  06/12/2006
• Antidepressants Can Increase Diabetes Risk in Certain Cases - If you are already at high risk for getting type 2 diabetes, antidepressant drugs can boost that risk, according to new research reported Saturday.  06/11/2006
• Antidepressants may boost diabetes risk - The use of antidepressants appears to increase the onset of diabetes in some high-risk individuals, according to a government-funded study announced Saturday.  06/11/2006
• Merck diabetes drug effective alone or as add-on - A Merck & Co. diabetes pill awaiting U.S. approval was moderately effective at reducing blood sugar levels both as a stand-alone treatment and in combination with other oral medicines in a handful of late-stage clinical trials presented Saturday.  06/10/2006
• Easier-to-use diabetes drug passes test - Eli Lilly & Co. and Amylin, makers of the diabetes treatment Byetta, reported Saturday that a more convenient-to-use but experimental version of the drug successfully reduces blood-sugar levels.  06/10/2006
• Merck says diabetes drug shows promise vs. hypoglycemia - In its face-off with Novartis over the multi-billion dollar diabetes market, Merck revealed a study Saturday showing that its experimental drug Januvia slashed the risk of hypoglycemia more than sixfold while matching a generic drug's ability to reduce blood-sugar level.  06/10/2006
• Metabolex Initiates Phase 2/3 Trial of Metaglidasen in Patients With Type 2 Diabetes - Metabolex, Inc. announced today the initiation of a Phase 2/3 trial of its lead product candidate, metaglidasen, in patients with type 2 diabetes.  06/10/2006
• Newly Released Phase III Studies for JANUVIA(TM), Merck's Investigational Once-Daily Medicine for Type 2 Diabetes, - Newly released Phase III studies presented here today at the American Diabetes Association 66th Annual Scientific Sessions demonstrated that JANUVIA , Merck and Co., Inc.'s investigational oral, once-daily medicine for type 2 diabetes, significantly reduced blood sugar levels when used as monotherapy or as an add-on treatment to two commonly used therapies.  06/10/2006
• Merck hurries on diabetes drug - Merck & Co. said Monday that it expects to file earlier than expected for regulatory approval of an experimental combination drug for type 2 diabetes.  06/10/2006
• Phenomix diabetes drug enters phase II - Phenomix Corporation has initiated a phase II clinical trial of PHX1149, a novel orally administered inhibitor of DPP4 for the treatment of type 2 diabetes.  06/10/2006
• Novartis, Merck Face Off Over New Diabetes Drugs - Novartis's Galvus and Merck's Januvia stand to enter the lucrative -- but highly competitive -- market of oral treatments for Type 2 diabetes. Both have been touted by analysts as potential $1 billion-a-year plus sellers.  06/09/2006
• Incyte begins phase I diabetes study - Incyte Corporation has initiated a phase I clinical trial to evaluate the potential of INCB13739 as a new treatment for type 2 diabetes.  06/09/2006
• Positive data for Depomed diabetes drug - A phase III trial of Depomeds Glumetza, a once-daily metformin tablet for the treatment of type 2 diabetes mellitus, has shown that adding the drug to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone. 06/09/2006
• Positive Data for Depomed Diabetes Drug - A phase III trial of Depomed's Glumetza, a once-daily metformin tablet for the treatment of type 2 diabetes mellitus, has shown that adding the drug to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone. 06/09/2006
• Eli Lilly and Alkermes Progressing With Diabetes Safety Study - Eli Lilly and Alkermes have completed patient enrollment in a pivotal safety study required for registration for their AIR inhaled insulin system, which is being investigated as an innovative treatment option for diabetes.  06/07/2006
•  DepoMed Releases Diabetes Drug Results - Biotechnology company DepoMed Inc. on Wednesday said results from a late-stage clinical trial for its diabetes drug shows it can add to the efficacy of an existing treatment for Type 2 diabetes.  06/07/2006
• DepoMed Releases Diabetes Drug Results - Biotechnology company DepoMed Inc. on Wednesday said results from a late-stage clinical trial for its diabetes drug shows it can add to the efficacy of an existing treatment for Type 2 diabetes.  06/07/2006
•  Merck Hurries on Diabetes Drug - Merck & Co. said Monday it expects to file earlier than expected for regulatory approval of an experimental combination drug for type 2 diabetes.  06/07/2006
• Phenomix diabetes drug enters phase II - Phenomix Corporation has initiated a phase II clinical trial of PHX1149, a novel orally administered inhibitor of DPP4 for the treatment of type 2 diabetes.  06/10/2006
• Novartis, Merck Face Off Over New Diabetes Drugs - Novartis's Galvus and Merck's Januvia stand to enter the lucrative -- but highly competitive -- market of oral treatments for Type 2 diabetes. Both have been touted by analysts as potential $1 billion-a-year plus sellers.  06/09/2006
• Incyte begins phase I diabetes study - Incyte Corporation has initiated a phase I clinical trial to evaluate the potential of INCB13739 as a new treatment for type 2 diabetes.  06/09/2006
• Positive data for Depomed diabetes drug - A phase III trial of Depomeds Glumetza, a once-daily metformin tablet for the treatment of type 2 diabetes mellitus, has shown that adding the drug to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone. 06/09/2006
• Positive Data for Depomed Diabetes Drug - A phase III trial of Depomed's Glumetza, a once-daily metformin tablet for the treatment of type 2 diabetes mellitus, has shown that adding the drug to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone. 06/09/2006
• Eli Lilly and Alkermes Progressing With Diabetes Safety Study - Eli Lilly and Alkermes have completed patient enrollment in a pivotal safety study required for registration for their AIR inhaled insulin system, which is being investigated as an innovative treatment option for diabetes.  06/07/2006
• DepoMed Releases Diabetes Drug Results - Biotechnology company DepoMed Inc. on Wednesday said results from a late-stage clinical trial for its diabetes drug shows it can add to the efficacy of an existing treatment for Type 2 diabetes.  06/07/2006
• DepoMed Releases Diabetes Drug Results - Biotechnology company DepoMed Inc. on Wednesday said results from a late-stage clinical trial for its diabetes drug shows it can add to the efficacy of an existing treatment for Type 2 diabetes.  06/07/2006
•  Merck Hurries on Diabetes Drug - Merck & Co. said Monday it expects to file earlier than expected for regulatory approval of an experimental combination drug for type 2 diabetes.  06/07/2006
• Clinical trials will determine if diabetes drug helps hearts - Groundbreaking clinical trials are under way at Allegheny General Hospital to determine if a drug currently being used to treat diabetes could also be effective in repairing a damaged heart.  06/05/2006
• Dumaguing: Actos a logical diabetes drug of choice - Breakfast sessions in medical conferences, whether local or international, are usually not very popular. For one, it starts at 7:30 a.m. when most of the doctors are still curled up in bed, understandably catching up with sleep, which is luxury item if they are in their place of practice.  06/04/2006
• Clinical trials will determine if diabetes drug helps hearts - Groundbreaking clinical trials are under way at Allegheny General Hospital to determine if a drug currently being used to treat diabetes could also be effective in repairing a damaged heart.  06/05/2006
• Dumaguing: Actos a logical diabetes drug of choice - Breakfast sessions in medical conferences, whether local or international, are usually not very popular. For one, it starts at 7:30 a.m. when most of the doctors are still curled up in bed, understandably catching up with sleep, which is luxury item if they are in their place of practice.  06/04/2006
• Increased sensitivity to nerve signals keeps diabetes at bay - Nerve signals relayed directly to the pancreas after eating a meal play a critical role in normal blood sugar control, according to a report in the June 7, 2006, Cell Metabolism. Therefore, drugs that increase the sensitivity to such signals might offer a new approach to diabetes treatment, the researchers said. 06/06/2006
• (AFX UK Focus) 2006-06-05 14:58 GMT: Merck to file Januvia diabetes type II drug in 2006; earlier than expected - Merck & Co Inc said it expects to file a new drug application for its type 2 diabetes drug Januvia to the Food and Drug Administration in 2006, earlier than its initially anticipated 2007 date.  06/05/2006
• Researchers Pinpoint Causes Of Adverse Reactions To Popular Type 2 Diabetes Drugs - Used by several million people worldwide, rosiglitazone (RSG) is an oral agent that helps patients with type 2 diabetes to maintain good blood glucose levels by improving how their bodies use insulin.  06/02/2006
• Drug for Type 2 Diabetes helps with weight loss.  - Research shows that a new drug for Type 2 Diabetes has an interesting side effect, weight loss. That's great news for diabetics, and now some are wondering if it might help people who don't have diabetes lose weight too.  06/01/2006

Back to Top

May 2006

• Researchers Say New Drug Could Help Those With Diabetes - Diabetes patients may soon have one less thing to worry about.   05/27/200
• India, China to develop herbal cure for diabetes - Indian and Chinese doctors are jointly undertaking clinical trials to prove the efficacy of herbal plants that offer a cure for diabetes.  05/24/3006
• Doctors: New Diabetes Drug Induces Weight Loss - Type 2 diabetes has an interesting side effect -- weight loss. Some people are wondering if the new drug, Byetta, might help people who don't have diabetes lose weight, too.  05/23/2006
• Bristol-Myers drops diabetes drug -  Bristol-Myers Squibb has discontinued the development of its type 2 diabetes candidate muraglitazar after the company decided further clinical trials to determine the safety of the drug were not worthwhile.  05/23/2006
• Topical Hedgehog Agonist Accelerates Wound Healing in Diabetes  - Curis, Inc. , a therapeutic drug development company, today announced the publication of preclinical data in the journal Circulation, showing that topical Sonic Hedgehog gene therapy accelerated wound healing in an animal model of diabetes.  05/23/2006
• Groundbreaking Cancer and Diabetes Therapies, Drug Delivery Modes Highlight Florida Tech Transfer Conference Agenda - 05/10/2006
• Diabetes drug might help the brain recover - A provocative new theory suggests that one root cause of Alzheimer's disease is linked to diabetes - a theory about to be tested in thousands of Alzheimer's patients given the diabetes drug Avandia in hopes of slowing brain decay.  05/10/2006
• Antidepressant drug may prevent recurrence of depression in patients with diabetes - A team of researchers at Washington University School of Medicine in St. Louis found that an antidepressant medication may reduce the risk of recurrent depression and increase the length of time between depressive episodes in patients with diabetes.  05/08/2006
• Safety concerns halt work on diabetes drug - AstraZeneca PLC. said it has halted work on a new diabetes drug because of safety concerns, its second...  05/08/2006
• AstraZeneca pulls late stage diabetes drug - AstraZeneca has discontinued development of its diabetes drug Galida after phase III trials suggested that the drug would not provide significant benefit over already available therapies for the disorder.  05/06/2006
• Diabetes medication may slow Alzheimer's  - Brain-sugar link probed A diabetes drug used to regulate glucose metabolism may help treat Alzheimer's, according to a new study.  05/05/2006
• Diabetes drug to be tested on Alzheimer's patients  - A new theory suggests that one cause of Alzheimer's disease is linked to diabetes - a theory about to be tested in thousands of Alzheimer's patients given the diabetes drug Avandia in hopes of slowing brain decay.  05/02/2006
• GENFIT Initiates Phase II Clinical Trials With GFT14 To Tackle Cardiometabolic Risk - Phase I results revealed very good tolerance in healthy volunteers as well as an excellent security profile for GFT14, one of the medical candidates that GENFIT is developing to tackle cardiometabolic risk.   05/03/2006
• ISTA Pharmaceuticals Reports Simple Model Predicts Treatment Success With Vitrase(R) in Vitreous Hemorrhage Associated with Diabetes - ISTA Pharmaceuticals, ( Nachrichten ) Inc. announced today details of two scientific poster presentations that describe the first predictive model for treatment success with Vitrase(R) (Ovine Hyaluronidase) in managing vitreous hemorrhage associated with diabetes.  05/01/2006

Back to Top

April 2006

• Dumaguing: Euglo Plus is best made even better  - EUGLUCON is probably the most reliable and efficacious oral anti-diabetes drug used in the control of elevated blood sugar. Euglucon, through it 35 years of use, has been the most remarkable, if not the original trade name of Glibenclamide.  04/29/2006

• PhytoMedical investigates unique diabetes drugs - PhytoMedical Technologies has revealed that its research into novel, insulin enhancing treatments will actively focus on the development of a new class of specific polyphenolic compounds, which, the company says, are distinct from existing classes of diabetes drugs.  04/27/2006

• Diabetes Drug May Prevent Alzheimer's - Clinical trials now under way are testing a once-radical theory: The cause of Alzheimer's disease is linked to diabetes.  04/26/06
• Transition Therapeutics Completes Target Enrollment for Type II Diabetes Clinical Trial of Lead Regenerative Product, - Transition Therapeutics Inc. , announces today the completion of target enrolment for an exploratory Phase IIa clinical trial of its lead regenerative therapy, E1-I.N.T., in type II diabetes patients and provides an update on the enrolment of patients in the type I diabetes clinical trial.  04/25/06
• Type 1 Diabetes Patients on Technosphere Insulin Showed HbA1c Improvements, Low Post-Prandial Glucose Fluctuations, and .. - MannKind Corporation today announced results from a Phase 2 clinical study of inhaled insulin in people with Type 1 diabetes.  04/19/06
• Emisphere Completes Enrollment For Phase II Oral Insulin Clinical Trial  (India) 04/16/06
• Singapore's biotech pipeline show promise - Singapore is betting on a clutch of top international scientists to come up with new wonder drugs to combat diseases such as cancer, dengue and disorders including diabetes.  04/14/06
• Curry Colouring And Fat Mix Could Help Diabetics.  Brisbane immunologist Dr Brendan O'Sullivan hopes to put a dent in skyrocketing rates of diabetes in Australia by creating a new treatment for Type 2 diabetes.   04/13/06
• Depomed Data Published in Diabetes Care on Glumetza, an FDA-Approved Treatment for Type II Diabetes -
• Depomed, Inc. announced today that the results of its Phase III clinical trial with Glumetza, an FDA-approved, once-daily version of metformin for the treatment of Type II diabetes, were published in the April 2006 issue of Diabetes Care.  04/11/06
• Torrent's diabetes division launches Pregeb and Piopod - Torrent Pharma's newly launched diabetes division, AzuCa, has launched two major blockbusters, Pregeb (Pregabalin) and Piopod (Pioglitazone).  04/10/06

• Takeda Submits New Drug Application For Extended-release Type 2 Diabetes Medication, ACTOplus MetTM 04/06/06

Back to Top

March 2006

Back to Top